# Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer

> **NCT07458529** · PHASE2 · RECRUITING · sponsor: **Seventh Medical Center of PLA General Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Rectal Cancer, Adenocarcinoma
- Neoadjuvant Therapy
- Immunotherapy
- Probio-M9
- Tislelizumab
- Randomized

## Interventions

- **COMBINATION_PRODUCT:** CRT+PD-1 inhibitor+Probio-M9
- **COMBINATION_PRODUCT:** CRT+PD-1 inhibitor+placebo

## Key facts

- **NCT ID:** NCT07458529
- **Lead sponsor:** Seventh Medical Center of PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-10
- **Primary completion:** 2027-05-05
- **Final completion:** 2030-12-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07458529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07458529, "Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07458529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*